Comparative Pharmacology
Head-to-head clinical analysis: TARGRETIN versus ZENATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARGRETIN versus ZENATANE.
TARGRETIN vs ZENATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
300 mg/m2 orally once daily.
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion.
Category C
Category C
Retinoid
Retinoid